Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The product is backed by required scientific proof and comparative bioequivalence studies
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
